Phase II study of a PARP inhibitor, talazoparib, in HER2-metastatic breast cancer (MBC) with a somatic BRCA1/2mutation identified in a cell-free DNA or tumor tissue genotyping assay

被引：0
|
作者：
Vidula, Neelima
Damodaran, Senthil
Bhave, Manali A.
Blouch, Erica
Ogbenna, Ogadinma
Flaum, Lisa E.
Shah, Ami N.
Abramson, Vandana G.
Cristofanilli, Massimo
Sparano, Joseph A.
Ostrer, Harry
Horick, Nora K.
Rugo, Hope S.
Bardia, Aditya
机构：
[1] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[3] Emory Univ, Sch Med, Atlanta, GA USA
[4] Massachusetts Gen Hosp, Boston, MA USA
[5] Northwestern Med Grp, Chicago, IL USA
[6] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA
[7] Vanderbilt Univ, Nashville, TN USA
[8] Weill Cornell Med, New York, NY USA
[9] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA
[10] Albert Einstein Coll Med, Bronx, NY USA
[11] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[12] UCLA, Hlth Jonsson Comprehens Canc Ctr, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS1143
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA).
    Litton, Jennifer Keating
    Blum, Joanne Lorraine
    Im, Young-Hyuck
    Martin, Miguel
    Mina, Lida A.
    Roche, Henri Hubert
    Rugo, Hope S.
    Visco, Fran
    Zhang, Charlie
    Lokker, Nathalie Andrienne
    Lounsbury, Debra L.
    Eiermann, Wolfgang
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [42] Final results of a phase II trial of trabectedin (T) in triple-negative, HER2-positive, and BRCA1/2 germ-line-mutated metastatic breast cancer (MBC) patients (pts)
    Tedesco, K. L.
    Blum, J. L.
    Goncalves, A.
    Lubinski, J.
    Osborne, C. R. C.
    Lardelli, P.
    Tercero, J. C.
    Florez, A.
    Holmes, F. A.
    Delaloge, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [43] Impact of pathogenic germline BRCA1/2 and PALB2 mutations and tumor aneuploidy in patients with HR+/HER2-metastatic breast cancer treated with CDK4/6 inhibitors
    Antras, Jesus Fuentes
    El Ghamrasni, Samah
    Zou, Jinfeng
    Dou, Aaron
    Elliott, Mitchell J.
    Avery, Lisa
    Bratman, Scott Victor
    Cescon, David W.
    Bedard, Philippe L.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [44] Reversion and non-reversion mechanisms of resistance (MoR) to PARP inhibitor (PARPi) or platinum chemotherapy (chemotx) in patients (pts) with BRCA1/2-mutant metastatic breast cancer (MBC).
    Waks, Adrienne Gropper
    Cohen, Ofir
    Kochupurakkal, Bose
    Kim, Dewey
    Wander, Seth Andrew
    Buendia-Buendia, Jorge
    Helvie, Karla
    Matulonis, Ursula A.
    Krop, Ian E.
    Tolaney, Sara M.
    Winer, Eric P.
    D'Andrea, Alan D.
    Shapiro, Geoffrey
    Lin, Nancy U.
    Wagle, Nikhil
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [45] SU2C phase Ib study of pan-PI3K inhibitor BKM120 with letrozole in ER+/HER2-metastatic breast cancer (MBC).
    Mayer, Ingrid A.
    Abramson, Vandana Gupta
    Balko, Justin M.
    Isakoff, Steven J.
    Kuba, Maria Gabriela
    Sanders, Melinda
    Forero-Torres, Andres
    Yap, Jeffrey T.
    Van Den Abbeele, Annick D.
    Li, Yisheng
    Arteaga, Carlos L.
    Winer, Eric P.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [46] Estrogen receptor 1 (ESR1) mutations in circulating tumor DNA (ctDNA) from patients with ER+/HER2-metastatic breast cancer (mBC) treated with lasofoxifene plus abemaciclib in the ELAINE 2 study
    Damodaran, Senthil
    Moore, Halle
    O'Sullivan, Ciara C.
    Plourde, Paul V.
    Riordan, Gary
    Sloane, Hillary S.
    Tripathy, Debu
    Carroll, Dominic
    Portman, David J.
    CANCER RESEARCH, 2023, 83 (05)
  • [47] TBCRC 048 (olaparib expanded) expansion cohorts: Phase 2 study of olaparib monotherapy in patients (pts) with metastatic breast cancer (MBC) with germline (g) mutations in PALB2 or somatic (s) mutations in BRCA1 or BRCA2
    Tung, Nadine M.
    Robson, Mark E.
    Nanda, Rita
    Li, Tianyu
    Vinayak, Shaveta
    Shah, Payal Deepak
    Khoury, Katia
    Kimmick, Gretchen Genevieve
    Santa-Maria, Cesar Augusto
    Brufsky, Adam
    Demeo, Michelle
    Vieira, Joao Pedro
    Carey, Lisa A.
    Wulf, Gerburg M.
    Domchek, Susan M.
    Krop, Ian E.
    Wolff, Antonio C.
    Winer, Eric P.
    Garber, Judy Ellen
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [48] The Talazoparib Beyond BRCA (TBB) trial: A phase II clinical trial of talazoparib (BMN 673) in BRCA1 and BRCA2 wild-type patients with (i) advanced triple negative breast cancer (TNBC) and homologous recombination deficiency (HRD) as assessed by myriad genetics HRD assay, and (ii) advanced HER2-negative breast cancer (BC) with either a germline or somatic mutation in homologous recombination (HR) pathway genes
    Afghahi, A.
    Chang, P-J
    Ford, J. M.
    Telli, M. L.
    CANCER RESEARCH, 2016, 76
  • [49] BPI-16350, a novel promising CDK4/6 inhibitor for HR+/HER2-metastatic breast cancer (MBC): Results from a phase I study
    Zhang, Jian
    Liu, Rujiao
    Gao, Shuiping
    Chen, Wenyan
    Han, Xinghua
    Ma, Yanjie
    Ding, Lieming
    Wang, Jiabing
    Lan, Hong
    Hu, Xichun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [50] Phase I/Ib study of the PARP inhibitor olaparib (O) with carboplatin (C) in BRCA1/2 mutation carriers with breast or ovarian cancer (Br/OvCa) (NCT00647062).
    Lee, Jung-Min
    Annunziata, Christina M.
    Hays, John L.
    Noonan, Anne M.
    Minasian, Lori M.
    Zujewski, JoAnne
    Yu, Minshu
    Ji, Jiuping Jay
    Sissung, Tristan
    Houston, Nicole D.
    Kohn, Elise C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345